Novel Class of Preventive Treatments for Migraine
Anti-calcitonin gene-related peptide monoclonal antibodies are the first approved pharmacologic treatments developed explicitly for the prevention of migraine.
Anti-calcitonin gene-related peptide monoclonal antibodies are the first approved pharmacologic treatments developed explicitly for the prevention of migraine.
The American Heart Association released interim guidance on resuscitation care in patients with known or suspected COVID-19.
Older teens may have similar risk factors for prescription opioid overdose as adults.
Eight percent of U.S. adults aged 35 years and older receive all services; 4.7 percent receive none
Investigators sought to evaluate the efficacy and tolerability of sTMS for migraine prevention.
Bed rest is not superior to early mobilization or fluid supplementation for reducing the incidence of postdural puncture headache.
Monthly subcutaneous injections of galcanezumab at either 120 mg or 300 mg were effective for preventing migraines.
The included trials looked at magnesium administration among those with menstrual migraine, migraine with and without aura, and standard migraine symptoms.
Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.
The FDA has approved 2 new migraine treatment devices to stop and prevent migraine attacks in adults.